U.S. Markets
Stryker (SYK) Q2 2026 (USD) Adj. EPS 3.69 (exp. 3.49), Revenue 6.6bln (exp. 6.58bln)
StockNow breaking-news AI analysis
Stryker outperformed Q2 expectations and sharply raised Q3 guidance, signaling a strong recovery from earlier operational disruptions and robust demand across its medical technology portfolio.
News detail
Sees Q3 Adj. EPS USD 14.95-15.10 (exp. 14.35)
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
